Abaloparatide at 80 µg/day increased lumbar spine bone density by 11.5% over 48 weeks in postmenopausal women with osteoporosis, with mild side effects that weren't dose-dependent.
+11.5% spine BMDThe 80 µg abaloparatide dose increased lumbar spine bone mineral density by 11.5% over 48 weeks — one of the strongest anabolic bone responses seen for any osteoporosis treatment
What the researchers found
Abaloparatide — a synthetic peptide analog of parathyroid hormone-related protein (PTHrP) — dose-dependently increased bone mineral density at all measured sites in postmenopausal Japanese women with osteoporosis over 48 weeks. The 80 µg dose produced striking results: 11.5% increase in lumbar spine BMD, 2.9% increase at total hip, and 2.4% at femoral neck. Even the lower 40 µg dose showed significant improvement (6.6% lumbar spine).
Bone formation markers (serum PINP) increased rapidly — by 67.3% and 140.7% at the 40 and 80 µg doses — indicating strong bone-building activity. Bone resorption markers (serum CTX) increased more slowly and modestly (16.4% and 34.5%), suggesting a favorable anabolic window where bone formation outpaces breakdown. Adverse events were mild to moderate and not dose-dependent.
Why it matters
Abaloparatide (brand name Tymlos) is an FDA-approved peptide drug for osteoporosis that competes with teriparatide (Forteo). This phase 2 study in Japanese women establishes dose-response efficacy in an East Asian population, supporting global applicability. The 11.5% lumbar spine BMD increase in under a year is among the strongest anabolic responses seen for any osteoporosis treatment, and the favorable bone formation-to-resorption ratio is a key advantage over some competing therapies.
The numbers in context
48-week treatment · 40 µg and 80 µg doses vs placebo · Lumbar spine BMD: +6.6% (40 µg) and +11.5% (80 µg) vs placebo · Total hip: +1.6% and +2.9% · Femoral neck: +1.5% and +2.4% · PINP: +67.3% and +140.7% · CTX: +16.4% and +34.5% · Adverse events mild/moderate, not dose-dependent
How the study worked
This was a randomized, double-blind, placebo-controlled, dose-finding phase 2 study in postmenopausal Japanese women at high fracture risk. Participants received daily subcutaneous injections of placebo, 40 µg, or 80 µg abaloparatide for 48 weeks. The primary endpoint was change in lumbar spine BMD. Secondary endpoints included total hip and femoral neck BMD at multiple timepoints, and bone turnover markers (PINP for formation, CTX for resorption).
Who was studied
Postmenopausal Japanese women with osteoporosis at high fracture risk
What this study cannot tell us
The abstract doesn't report the specific number of participants, though phase 2 dose-finding studies typically enroll modest numbers. The study was conducted in Japanese women only, limiting direct generalizability to other populations. 48 weeks is relatively short for an osteoporosis treatment — fracture prevention data requires longer follow-up. Fracture reduction was not an endpoint in this dose-finding study.
How to read the evidence
This is a randomized, double-blind, placebo-controlled phase 2 trial — a rigorous study design. The clear dose-response relationship strengthens confidence in the findings. However, the undisclosed sample size (likely modest for phase 2), single-population focus, and lack of fracture endpoints slightly limit the evidence grade.
When this study was published
Published in 2023, this is recent data supporting abaloparatide's global development program. Abaloparatide is already FDA-approved in the US, and this study supports further clinical development in Japan.
The bigger picture
Abaloparatide is part of a class of bone-building peptide drugs (anabolic agents) that represent a paradigm shift in osteoporosis treatment. Unlike older drugs that simply slow bone loss, these peptides actively build new bone. This dose-finding study supports 80 µg as the optimal dose for further development in Japanese women, expanding the drug's evidence base beyond Western populations and potentially toward regulatory approval in Japan.
Questions still open
- Does the 11.5% BMD increase translate to proportional fracture risk reduction in this population?
- How does abaloparatide's efficacy in Japanese women compare to teriparatide and romosozumab in the same population?
- What happens to bone density after abaloparatide is discontinued — is sequential therapy with an anti-resorptive needed to maintain gains?
Common questions
What is abaloparatide and how does it build bone?
How does an 11.5% increase in bone density translate to real-world benefits?
Read the original research
Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.
Journal of bone and mineral metabolism, 41(6), 807-816
Citation
Matsumoto, Toshio; Sone, Teruki; Yamashita, Akiko; Inoue, Tetsuo. (2023). Abaloparatide dose-dependently increases bone mineral density in postmenopausal women with osteoporosis: a phase 2 study.. Journal of bone and mineral metabolism, 41(6), 807-816. https://doi.org/10.1007/s00774-023-01455-6